Effects of two chemotherapy regimens, anthracycline-based and CMF, on breast cancer disease free survival in the Eastern Mediterranean Region and Asia: A meta-analysis approach for survival curves

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 2013-2017

  Zare, Najaf ^a,c   Ghanbari, Saeed ^a,c   Salehi, Alireza ^b,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant chemotherapy regimens; Disease free survival curve; Meta analysis; Multivariate mixed model

Indexed keywords

EID: 84880406839     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.2013     Document Type: Article

References (25)

1. Al-Moundhri M, Al-Bahrani B, Pervez I, et al (2004).The outcome of treatment of breast cancer in a developing country-oman. The Breast, 13, 139-45.
2. Arends L.R, Myriam Hunink M.G, Stijnen Th (2008).Metaanalysis of summary survival curve data. Statistics in Med, 27, 4381-96.
3. American Cancer Society (2010).Breast cancer facts & figures .Atlanta; American Cancer Society, Inc.
4. Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Hlth J, 16, 1032-8.
5. Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35-42.
6. Brunner, Suddarth's (2008). Textbook of medical-surgical nursing. 11th Edition, chapter 1.
7. Dear KBG (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 50, 989-1002.
8. Duolao W, Ameet B, Felicity C (2006). A Practical Guide to Design, Analysis, and Reporting Clinical Trials. London Remedica, chapter 38.
9. Dersimonian R, Kacher R (2007). Random-effect model for meta-analysis of clinical trials: an update. Contemp Clinical Trials, 28, 105-14.
10. Di Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42.
11. Faradmal J, Kazemnejad A, Khoda BR, Hajizade E, Gohari MR (2010). Comparing three adjuvant chemotherapy regimens after modified radical mastectomy in breast cancer patients using log-logistic model. Sci J Semnan Univ Med Sci, 11, 279-86.
12. Hedges LV, Vevea JL (1998). Fixed and random effects model in meta-analysis. Psychological Methods, 3, 486-504.
13. Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12-25.
14. Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247-57.
15. Kleinbaum D (2004). Survival analysis a self- learning text. Springer.
16. Kuru B, Camlibel M, Dine S, et al (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res, 3, 363-71.
17. Katalinic A, Pritzkuleit R, Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care, 4, 75-80.
18. Kim K, Chie EK, Han W, et al (2011).Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori, 97, 280-5.
19. Lian-Fang Li, Xiao-Jing Xu, Zhao Y, et al (2008). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7.
20. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in iran: an epidemiological review. The Breast J, 13, 383-91.
21. Sakakibara M, Nagashima T, Kadowaki M, et al (2009). Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol, 16, 2470-8.
22. Wong ZW, Ang PCS (2008). Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in asian women with metastatic breast cancer. The Breast, 17, 517-22.
23. Wang SH, Yanxia S, Yuan ZH, et al (2011). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol, 11, 9964-72.
24. Yan PW, Huang XE (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/ epirubicin/ cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
25. Zhang J, Yan LIU (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejinang University Science, 9, 5-9.